Karuna Therapeutics

Karuna Therapeutics' Mission and Focus

Karuna Therapeutics is dedicated to the development of transformative medicines aimed at addressing psychiatric and neurological conditions. By leveraging advanced scientific research and innovative approaches, the company seeks to improve the lives of patients suffering from severe mental health disorders. Their strategic focus is on creating therapeutics that can significantly alter the treatment landscape for conditions such as schizophrenia and psychosis in Alzheimer's disease, aiming to fill unmet medical needs and enhance patient outcomes.

Karuna Therapeutics' Clinical Pipeline

A key component of Karuna Therapeutics' clinical pipeline is KarXT, an investigational treatment designed to target both schizophrenia and psychosis in Alzheimer's disease. KarXT represents a novel approach by combining xanomeline and trospium to mitigate psychiatric symptoms without the side effects typically associated with current treatments. This investigational drug is in various stages of clinical trials, showing promise for providing a new therapeutic option for patients with these debilitating conditions.

Karuna Therapeutics' Partnership with Zai Lab

Karuna Therapeutics has entered a strategic partnership with Zai Lab to advance the development, manufacturing, and commercialization of KarXT in Greater China. This collaboration aims to leverage Zai Lab's extensive regional expertise and infrastructure to bring KarXT to a broader patient population. The partnership underscores Karuna's commitment to expanding its global footprint and ensuring that innovative treatments are accessible to patients worldwide.

Karuna Therapeutics' Collaboration with PsychoGenics

In its quest to discover new treatments for severe neuropsychiatric conditions, Karuna Therapeutics collaborates with PsychoGenics, a leader in phenotypic drug discovery. This partnership focuses on identifying and developing novel drug candidates that can address significant unmet needs in mental health. PsychoGenics' advanced technologies and expertise in behavioral research complement Karuna's mission to transform the therapeutic landscape for psychiatric conditions through innovative and effective treatments.

Karuna Therapeutics' Policy on Expanded Access

Karuna Therapeutics currently does not accept or grant requests for expanded access to any of its investigational drugs outside of clinical trials. This policy ensures that the company's investigational treatments are distributed in a controlled and scientifically rigorous manner, prioritizing patient safety and the integrity of the clinical trial process. By focusing on clinical trials, Karuna aims to gather the necessary data to secure regulatory approvals and bring their innovative therapies to the market as quickly and safely as possible.